• Quantum computing can be a tool to help enterprises navigate the ongoing disruption and complexity of today’s business world
• Quantum adoption is expected to grow substantially over next 15-30 years, practical quantum solutions are already here, and demand for quantum-ready talent is rapidly accelerating
• Governments around the world have developed quantum adoption and investment strategies

As businesses encounter challenging computational problems that classical computers are ill-equipped to solve efficiently, or at all, the value of quantum computing is becoming increasingly apparent. Quantum can be used to tackle data-intensive computations in the areas of logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, financial modeling, and more, and businesses are planning to increase their near-term commitments to this nascent technology, per research from Hyperion Report.

In this context, business leaders should embrace a “quantum mindset” in order to more effectively navigate today’s ongoing disruptions and complexity, according to D-Wave Quantum (NYSE: QBTS) President and CEO Dr. Alan Baratz. In a recent article published on LinkedIn entitled Shifting to Quantum Mindset: Why the Time is Now, Baratz explains why he believes quantum computing is here to stay. He outlines how quantum computing is progressing on multiple fronts, generating significant market potential and talent demand, amid increasing business and government investments in the technology on a worldwide basis (https://ibn.fm/kNSo5).

“The imperative is to adopt a quantum mindset that is ever-present,” Baratz states. “Now is the time to bring quantum to the forefront of decision-making when it comes to tech investment, business operations, national and global competitiveness, and workforce development.”

With quantum popularity increasing, so does the need for talent capable of working with it. Although quantum physicists are a part of the rapidly developing technological landscape, anyone with a computer science background who can code in Python can get started working with quantum.

As various governments map out national quantum strategies and increase funding, they are also targeting quantum education and building quantum-hybrid solutions to solve public sector challenges. Countries including the UK, Canada, France, and India have recently shared updated quantum strategies that map out adoption and investment plans, showing their long-term commitments to the technology.

According to Boston Consulting Group, the quantum computing market will grow to between $450 billion and $850 billion over the next 15 to 30 years (https://ibn.fm/ZKwEn). Hyperion Research estimates that 80% of quantum early adopters are planning to increase their commitment to quantum in the next two or three years, with one-third of them expected to invest at least $15 million in quantum (https://ibn.fm/n2aGv).

D-Wave is working with customers to build commercial quantum-hybrid applications today. D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used by some of the world’s most advanced enterprises. These customers include blue-chip industry leaders such as Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, NEC Corporation, Pattison Food Group, DENSO, and Lockheed Martin.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Methane is believed to cause climate change by trapping 86 times more heat in the atmosphere than carbon dioxide
• EVGIF advances RNG technology that negates the effects of methane while combatting carbon dioxide production caused by burning natural gas
• The RNG production process produces biogas that can be refined and purified to create pipeline-quality RNG, which can be injected into current networks
• EverGen aims to create an RNG network comprising 20+ facilities across Canada within five years

Methane is released while producing and transporting coal, natural gas, and oil. As a result, climate justice activists believe methane causes climate change by trapping 86 times more heat in the atmosphere than carbon dioxide alone (https://ibn.fm/M80Wk). Fortunately, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), a Canadian renewable energy company, offers a solution through renewable natural gas (“RNG”) technology that negates the effects of methane while combatting carbon dioxide production associated with burning natural gas.

Experts from the World Economic Forum believe that methane emissions must drop to reach climate goals (https://ibn.fm/bErq9). According to the organization, methane emissions caused roughly 30% of global temperature increases since industrialization, and the problem is getting worse as emissions reach record levels.

RNG technology provides a solution that is more than just carbon-neutral – it’s carbon negative due to its ability to remove methane that otherwise would be produced when organic matter decomposes. The RNG production process leverages a process called anaerobic digestion that uses microorganisms to break down organic materials such as sewage sludge, organic waste, and animal manure in an enclosed, oxygen-free container (https://ibn.fm/FZe1A). The process then creates two primary products: digestate – a by-product that can be used as crop fertilizer, and biogas – a renewable source of methane gas.

Biogas can be refined and purified to create RNG – a pipeline-quality gas that can be injected into existing networks. EverGen aims to develop such a network comprising 20+ facilities within five years by acquiring, managing, and developing RNG and waste-to-energy projects nationwide.

Current projects in the company’s portfolio include Fraser Valley Biogas, Sea to Sky Soils, and Net Zero Waste Abbotsford in British Columbia, and a 67% stake in Alberta-based GrowTEC. Across the country in Ontario, EverGen has a 50% stake in Project Radius – a portfolio of three large, on-farm, and late-stage development projects that can potentially produce up to 1.7 million GJ of RNG annually.

The company is based in British Columbia – a province that actively takes action to reduce overall greenhouse gas emissions by supporting projects that displace equivalent volumes of traditional natural gas with carbon-neutral RNG. “The more RNG we have, the less conventional natural gas we need,” said Jenelle De La Cour, a manager of renewable gas accounts with FortisBC (https://ibn.fm/cr9bd). “Every RNG project is a win for climate action.”

EverGen leads RNG adoption in Canada with a portfolio of carbon negative RNG projects across the country. The company is committed to unlocking the power of carbon negative RNG to combat climate change, improve sustainability, and help reach worldwide emission targets.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Canada-based Ucore Rare Metals Inc. is preparing to begin construction on a rare earth element (“REE”) processing plant in Louisiana that it says will be the first REE separation facility to operate at commercial scale in North America
• Currently, China dominates both REE feedstock supply and REE processing capacity on a global basis, generating concerns that it can control the world’s ability to build modern technologies and use its control to retaliate against countries in adversarial situations
• Modern technologies that rely on REEs for crucial magnets in their composition include phones, computers, household appliances, electric vehicles, solar panels, and wind turbines
• Ucore plans to provide 2,000 metric tons of total rare earth oxides (“TREOs”) annually by late next year, increasing that amount to 5,000 metric tons in 2026

Critical metals production innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is accelerating its efforts to establish a North American-focused supply chain for rare earth elements (“REEs”) since announcing in April that it had reached an agreement to lease an 80,800 square-foot brownfield facility in Alexandria, Louisiana for its first Strategic Metals Complex (“SMC”) facility for REE separation and oxide production.

The company has strengthened its financial position and is working to fulfill plans to launch construction of the Louisiana SMC this year, building to a production capacity of 2,000 metric tons of total rare earth oxides in 2024 and increasing it to 5,000 metric tons in 2026.

Rare earths are vital to many computerized application processes and, though plentiful around the world, tend to make up a small portion of the ores they are found in, requiring a labor-intensive methodology for extracting the REEs.

“It is critical that the United States leads in establishing the critical metals supply chain essential to a changing manufacturing landscape across North America,” Ucore Chairman and CEO Pat Ryan stated in an April 6 company news release (https://ibn.fm/JziR4). “The establishment of the Louisiana SMC in Alexandria represents one of these first building blocks and a significant contributor to the shift toward energy production and consumption diversification.”

China’s dominance of the REE production industries has created concerns in other nations about a potential monopoly on the market by the Asian behemoth. Two years ago, the country consolidated three of its dominant “Big 6” rare earth state-owned enterprises (“SOEs”) into one mega-conglomerate, which now controls up to a quarter of global mineral-bearing REEs and nearly two-thirds of the heavy rare-earth supplies within the country (https://ibn.fm/YQ3Rl). And China also operates roughly 60 percent of world REE production (https://ibn.fm/nq94g), allowing it to weaponize its resources when it wishes to maintain control in international conflicts.

“These minerals power phones and computers, household appliances, electric vehicles and batteries, solar panels, wind turbines, and so much more,” President Biden stated in February (https://ibn.fm/w8iNY). “When it comes to clean energy, China has spent years cornering the market on many of the materials that power the technologies that we rely on. … We can’t build a future that’s made in America if we ourselves are dependent on China for the materials that power the products of today and tomorrow.  And this is not anti-China or anti anything else; it’s pro-American.”

Ucore’s Louisiana facility is expected to use the company’s 100 percent-owned Rapid SX (TM) technology, which has already been successfully piloted in Canada, to operate North America’s first rare earths separation facilities at scale.

“Absolutely we’re behind,” Special Presidential Coordinator Amos Hochstein said in a CNBC interview (https://ibn.fm/J1zOE). “We have to recognize that we have not invested, and that’s what the United States is trying to do now. … We have to learn from what we went through in the oil and gas energy space, as we transition to a new energy market that relies still on natural resources.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

Clinical research, contract specialists, clinical operations, regulatory affairs, and legal strategists will all convene at Dynamic Global Events’ (“DGE’s”) 4th Clinical Trial Agreements Forum, returning to in-person learning on August 29-30 in Philadelphia, PA. As the only industry forum to specifically focus on Clinical Trial Agreements (‘‘CTAs’’), this will be a must-attend for legal, regulatory, and clinical contracting professionals who want to stay ahead of the curve on the latest strategies to overcome the industry’s most pressing challenges.

The two-day conference is designed to provide a unique networking and learning experience on the key insights and the latest trends, best practices, and most critical factors impacting the effectiveness and efficiency of your Clinical Trial Agreements. Attendees will enrich their knowledge of how best to structure CTAs that safeguard clinical data in today’s constantly evolving ecosystem—and walk away armed with actionable strategies to expedite timelines and achieve contracting success.

Offering both in-person registrations to maximize networking opportunities and possibilities for organizational improvement, and virtual format to attend for those who cannot make it on-site. On-demand access will also be available to watch the recording of the full conference as well.

No other conference goes into as much detail on these timely and crucial topics:

• Explore CTAs in the Context of DCTs and Remote Monitoring
• Key Considerations for CTA Drafting to Avoid Uninsured Losses
• Accelerate Indemnification Clause Negotiations and Timelines
• Protect IP Rights and Prioritize Data Confidentiality
• Create and Negotiate Master Budgets to Reduce Bottlenecks
• Deep Dive into GDPR: Clarifications and Impact on CTAs
• Structure Patient Injury Language in Subcontracts
• Unravel Difficulties Surrounding Investigator-Initiated CTA clauses
• Effectively Reach Consensus Between Sponsors, Sites, and CROs

Key Takeaways:

DGE’s 4th conference focuses specifically on the most critical challenges surrounding Clinical Trial Agreements and how to overcome them.

• Professional speakers from a wide variety of disciplines and backgrounds—including biopharma, research sites, academia, legal experts, and many more luminaries
• Located in the comfortable and beautiful city of Philadelphia, at the ‘Inn at Penn’, a Hilton Hotel
• Registration is available for in-person or virtual attendance

Behind the scenes:

Dynamic Global Events manages a wide-ranging portfolio of educational gatherings for professionals in the life sciences, utilizing in-person, virtual, and hybrid access capabilities. Its content-driven team provides narrowly focused opportunities for professionals by engaging experts who can address specific challenges and help to develop strategies for creating success.

DGE’s customer-first culture helps life sciences professionals differentiate between content and commercialism while promoting the exchange of critical information between life science professionals and suppliers who support shared goals.

For more information about this event, please visit https://ibn.fm/6ZQEr.

Blockchain technology experts, crypto enthusiasts, investors, and business owners are invited to attend the Web3 Berlin Conference to be held in Berlin, Germany, June 10-11, 2023. As the technological world is on the verge of evolution, the much-awaited Web3 Berlin Conference is set to unveil the potential of associated disruptive technologies.

Hosting the prominent gathering of unique ideas and intellectual minds, Web3 Berlin Conference promises to celebrate technological innovation. The conference has a rich history of successful events, featuring engaging workshops and immersive panel discussions.

The keynote speakers will share insights into blockchain technology, decentralized applications (dApps), decentralized finance (DeFi), and non-fungible tokens (“NFTs”). Attendees will get a unique opportunity to meet visionaries who will share their expertise about decentralized technologies investment opportunities, industry trends, and regulatory challenges.

A Groundbreaking event for Networking and Social Gathering

Web3 Berlin Conference will feature industry pioneers and renowned industry leaders who will share interactive sessions about the latest frameworks, tools, and methodologies for creating decentralized applications. Blockchain developers will get an opportunity to hone their skills and gain valuable insights into real-world projects.

The exhibition area of the conference will feature prominent blockchain companies and startups that will demonstrate the latest industry advancements. By providing ample networking and collaboration opportunities, this dynamic event will enable attendees to launch their innovative projects. Moreover, the Web3 ecosystem will provide them with an opportunity to meet like-minded individuals and crypto investment prospects.

The 2023 Web3 Berlin Conference is designed to nurture an inclusive community, forging new partnerships while driving the global acceptance of Web3 technologies. Interested participants can register now to avail early-bird rates and secure their spot at the epitome of the Web3 revolution.

To learn more, please visit https://ibn.fm/5mTk0.

• Global electrification depends on the availability of graphite to power lithium-ion batteries used in EVs and portable electronic devices
• The Ruby Graphite Deposit is the only combined graphite flake and vein graphite source in the U.S., Reflex secured the option to acquire a 100% stake in the project in 2022
• Reflex engaged Lone Star Tech Minerals to advance Ruby Graphite project, deliverables include a production plan, marketing strategy, customer database, and technical data sheet
• Biden Administration to award $2.8 billion to expand domestic EV battery manufacturing and graphite processing

The worldwide shift to electrification depends on the availability of graphite – a critical element needed to power lithium-ion batteries used in electric vehicles (“EVs”) and portable electronic devices.

The Ruby Graphite Deposit is the only combined graphite flake and vein graphite source in the United States. Acquired last year by Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), the Ruby Graphite Deposit is a low-cost opportunity to re-enter the market with recent samples assaying at 95.8% to 98.4% total carbon.

RFLXF is aiming to meet surging graphite demands by engaging with Lone Star Tech Minerals (“LSTM”), a Texas-based graphite and industrial minerals marketing consulting firm. Under the partnership, both companies will collaborate to conduct a competitive analysis and develop a market strategy for coated, spherionized, and purified graphite (“CSPG”) (https://ibn.fm/8OxLF).

“We are excited to partner with Lone Star Tech Minerals and leverage their marketing and technical experience,” said Paul Gorman, CEO of Reflex Advanced Materials Corp. “Lone Star’s extensive knowledge of the CSPG industry will be invaluable as we aim to deliver high-quality, custom graphite products to a wide range of industry uses and chemistries to the North American supply chain.”

Under the agreement terms, RFLXF and LSTM will develop a production plan, marketing strategy, and customer database. LSTM will also produce a technical data sheet that aims to qualify potential customers requiring CSPG to test and evaluate the efficacy and compatibility of a new, conductive, additive anode material in a chemistry or format required for their specific application.

“We are thrilled to come on board with Reflex Advanced Materials and provide our go-to-market, commercial and technical expertise,” said Chris Whiteley, CEO of Lone Star Tech Minerals. “We look forward to the partnership and leveraging our extensive industry knowledge and marketing expertise, including downstream battery OEMs and other high tech end users of CSPG where margins are highest, and demand is still diverse and abundant.”

Graphite is critical for manufacturing battery electrodes, motors, and generators, as well as a lubricant in circuit breaker and switch production. EV manufacturers specifically prefer lithium-ion batteries over other technologies because they efficiently store and release lithium ions over multiple charge-discharge cycles, leading to longer driving ranges and shorter charging times.

Historically, the Ruby Graphite Deposit produced roughly 2,400 tons from 1902 to 1948. RFLX now holds mining rights for 755 hectares with 96 federal lode mining claims and will use targets identified using historical data and the 43-101 technical report dated January 31, 2023. The company submitted a permit application in March 2023 and plans to start implementing an initial plan to drill 3,500 meters at an average core depth of 130 meters this summer.

Chinese producers provide most of the graphite sold in North America today, raising concerns in Washington that the U.S. is overdependent on foreign sources (https://ibn.fm/jsjp5). To combat the problem, the U.S. Department of Energy plans to award $2.8 billion to expand domestic EV battery manufacturing, including graphite processing (https://ibn.fm/0Y42C). Reflex Advanced Materials are aiming to take advantage of these shifting economic conditions by expanding the Ruby Graphite Deposit in advance of increased demand.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• Digital money is replacing physical cash, and FEXD is developing mobile transaction platforms and services that are helping implement the coming changes in the fintech market
• FEXD plans to acquire and merge with companies that include country-based fintech pioneers with global scalability, fintech service providers, companies with large customer bases, and more
• The company is helping ensure humanity has a path forward from archaic and restrictive cash systems – reducing poverty, improving the lives of the unbanked, providing critical financial options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children

With plans to offer a diverse portfolio of fintech-related products and services for consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America, Fintech Ecosystem Development (NASDAQ: FEXD) continues to move forward in the service of underserved and overlooked markets within the global financial ecosystem. The FEXD management team has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector, driving the move to a cashless society.

Digital money is replacing physical cash, with consumers able to buy products and services anywhere in the world and make payments across borders. FEXD is developing mobile transaction platforms and services that are helping implement the coming changes – especially in underserved and overlooked markets like rural areas and Asia, the Middle East, Africa, and Latin America.

FEXD supports the United Nations’ Sustainable Development Goal to reduce cross-border transaction costs from 7 percent to 3 percent. The company’s use of advanced technology is lowering fintech costs and international fees for cross-border transactions.

The company’s growth strategy includes seeking the acquisition and merging of high growth fintech primarily operating in South Asia. The target companies that FEXD plans to acquire and merge with will help the company grow to $1 billion and more in annual revenues as a part of the global fintech ecosystem it is developing. The companies that FEXD plans to acquire/merge with will exhibit the following characteristics:

• Country-based fintech pioneers with the global scalability
• Fintech service providers that will benefit from integrating more advanced technologies
• Fintech companies with a large existing customer base
• A shared interest in making an impact by bringing mobile transaction services to under-served markets
• Growth-oriented management teams
• Attractive valuation

FEXD is committed to supporting the fintech and digital money processes in developing countries and cultures. Using its keen understanding of market needs in regions worldwide, the company is helping ensure humanity has a path forward from an unhygienic cash system – reducing poverty, improving the lives of the unbanked, offering securing and savings options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children.

According to McKinsey research, there are four major trends driving the growth of digital payments worldwide, especially in emerging markets like Africa and Southeast Asia, where low banking penetration allows payment providers to capture untapped potential and reach underserved populations. The first trend, the pandemic, accelerated the contactless digital payments frontier. Second, e-commerce continues to grow and evolve, with global volumes expected to increase by 12 to 15 percent annually by 2025. Third, the government is pushing for cashless payments to facilitate interoperability, plug tax leakages, and ensure effective aid distribution. Lastly, McKinsey points out investor appetites for digital payments, leading to a proliferation of payments-focused fintechs (https://ibn.fm/oOGOX).

Many areas of the world have severely underserved financial service markets. Millions of people require faster and cheaper ways to transfer money directly across borders to fund business transactions and provide support. Mobile money platforms provide a solution to the billions of people who own a cell phone but do not have access to a bank. FEXD services allow people in other countries to access USD online accounts that are FDIC insured.

For more information, visit the company’s website at www.FintechEcoSys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

• Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone
• The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone
• Estrone is a type of estrogen that can be reversibly made from estradiol in certain tissues within the female body
• The study HOR-A22-1 also revealed that DehydraTECH resulted in 1,500% and 12,500% higher exposure to estradiol and estrone over time, respectively, compared to the control
• Lexaria also announced the closing of a public offering that raised approximately $2 million in gross proceeds

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported that it had completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol (https://ibn.fm/ywP2y).

Performed in 20 female Sprague-Dawley rats, the pharmacokinetic study compared a DehydraTECH-estradiol formulation to a generic estradiol composition, both containing 10 mg/kg of estradiol, to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone. Once dosing was completed, blood was collected up to 48 hours post-dosing, with the concentration of estradiol and estrone determined thereafter.

Estradiol is a major female sex hormone and the most common form of estrogen in women of childbearing age. It is normally made in the ovaries (although it is also manufactured in the testicles in men, albeit in small quantities) but can be administered as an oral tablet, topical gel or patch, cream, or injection to reduce the symptoms of menopause and protect bone health. It is also found in birth control products. Put simply, estradiol is an important element of therapeutic products in the women’s health sector. On the other hand, Estrone is the only type of estrogen that females continue to manufacture after menopause. It is primarily made in the adrenal glands (in both males and females), although it is also reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver, a factor that informed the study’s measurement of estrone levels.

The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (“Cmax”) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL compared to the control’s 0.302 ng/mL.

Additionally, the study evaluated the area under the curve (“AUC”), a parameter that gave insight into the total delivery of estradiol over time as well as the extent of exposure to estrone. The AUC was 3.9 hr.ng/mL for estradiol and 32.6 hr.ng/mL for estrone when the DehydraTECH-processed composition was used. In comparison, the AUC after administering the control was non-detectable for both estradiol and estrone, as it was below 0.25 ng/mL, the lower limit of quantitation of the assay. This means the AUC findings were 1,500% and 12,500% greater than the control for estradiol and estrone, respectively.

Considered an additional step that is readily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical products, DehydraTECH has been shown to improve the proportion of the drug delivered into the bloodstream (bioavailability) and the absorption of drugs into the brain tissue. Among the drugs that can benefit from these improvements is oral estradiol, which has minimal bioavailability (2% to 10%) due to gut and liver metabolism (https://ibn.fm/kbdx1). This, according to Lexaria, often necessitates high dosages to achieve the desired beneficial effect; but this can, in turn, lead to unwanted side effects. Thus, incorporating DehydraTECH into the manufacturing process of oral estradiol and potentially other human hormone therapies may enhance their oral delivery.

The animal study HOR-A22-1, which is part of Lexaria’s efforts to pursue multiple paths to success by investigating several large market opportunities, represents a foray into the hormone replacement market estimated to grow from $31.06 billion in 2019 to an estimated $46.50 billion by 2027, a 5.1% CAGR (https://ibn.fm/PnAIK).

Meanwhile, Lexaria also announced the closing of its public offering of 2,106,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The offering generated approximately $2.0 million in gross proceeds.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Smart organizations are encouraged to meet certain standards and regulations to protect data against cybersecurity threats
• With more than 15 billion user credentials scattered across the dark web, the threat is real
• CEO notes that compliance is an important driver for security, and organizations should never view it as a mere technical nuisance

Complying with security requirements should be about more than just ticking off mandatory checkboxes, says CISO Global (NASDAQ: CISO) CEO David Jemmett (https://ibn.fm/dDN38). CISO Global, formerly Cerberus Cyber Sentinel Corp., works closely with companies to provide essential protection, and Jemmett is a recognized expert in the field of cybersecurity.

“Today, all organizations are required or encouraged to meet certain standards and regulations to protect their data against cybersecurity threats,” writes Jemmett in a guest essay for The Last Watchdog. “The regulations vary across countries and industries, but they are designed to protect customers from the threat of posed data breaches.”

That threat is real, notes Jemmett, citing estimates that currently more than 15 billion user credentials are scattered across the dark web. “The importance of compliance is clear to see,” he writes. “In spite of this, many organizations today still see compliance as a nuisance, rather than a business enabler. All too often, organizations will analyze compliance requirements and harden their systems and practices to meet them, without really thinking about their importance to the business. Instead, they will tick the mandatory checkboxes, even if security measures haven’t been enacted, and file the record away as quickly as possible.”

This approach is dangerous, explains Jemmett, noting that single “point-in-time” compliance doesn’t cut it in today’s threat landscape. “Compliance is no longer a ‘set and forget’ security framework,” he continues. “To keep up to speed in today’s evolving threat landscape, compliance is a process that must be maintained continuously.”

In his essay, Jemmett offers several tips to help companies implement an effective cybersecurity compliance strategy, providing timely, relevant protection against current as well as new and emerging threats. These suggestions include staying up-to-date with the evolving and growing attack surface, taking a risk-based approach and remembering that cybersecurity is a culture, not a product. “Compliance is an important driver for security, and organizations should never view it as a mere technical nuisance. Cybersecurity is a critical business enabler today, and those that get it right will excel. Those that get it wrong, and do not prioritize their defenses, could stand to lose everything,” Jemmett concluded.

CISO Global is gaining recognition as a leading provider of global cybersecurity and compliance as it rapidly expands by acquiring world-class cybersecurity, secured-managed services and compliance companies. These acquisitions bring top-tier talent to the CISO table, enabling the company to utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
• BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
• The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
• BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis

Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.

BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.

“Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (https://ibn.fm/jWiGl).

BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.

The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services (https://ibn.fm/ArbDX) to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.

Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (https://ibn.fm/FRmQg).

“The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (https://ibn.fm/IAcxF).

A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV